Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). Traditionally, MS was held to be a T-cell mediated disease, but accumulating evidence during the last decade also highlighted the crucial importance of B cells for the disease progression. Particularly, B cell depleting therapies (BCDTs), have demonstrated striking efficacy in suppressing inflammatory disease activity in relapsing-remitting MS. However, a detailed understanding of the role of B cells in the pathogenesis of MS is still lacking, and by extension also the mechanism of action of BCDTs. In this longitudinal multi-center study, we investigated the impact of BCDTs on the immune landscape in MS patients using high-dimensional single-cell immunophenotyping (cytometry by time-of-flight; CyTOF). Algorithm-guided analyses revealed phenotypic changes in the newly reconstituted B cell compartment after BCDT, as well as a marked specific reduction of circulating T follicular helper (Tfh) cells with a concomitant upregulation of CD27 surface expression in memory T helper cells and Tfh cells. These findings indicate a costimulatory mechanism in the CD27/CD70 signaling pathway, through which B cells sustain the activation of pathogenic T cells. Disrupting the CD27/CD70 signaling axis via BCDTs provides a potential explanation for its clinical efficacy.
One Sentence Summary B cell depletion contracts follicular T helper cells, displaces memory-to-naïve ratio and impairs CD27 signaling in T helper cells.
Competing Interest Statement
This study was partially funded by Roche Pharma. T.O. has received advisory board/lecture honoraria and unrestricted MS research grants from Biogen, Sanofi, Merck, and Novartis, none of which has any relation to the current study. Other than that, the authors declare no conflict of interest.
Funding Statement
This work received project funding from Roche Pharma (to B.B.) and from the European Research Council (ERC) under the European Unions Horizon 2020 research and innovation program grant agreement no. 882424 (to B.B.) the Swiss National Science Foundation (733 310030_170320 and 310030_188450 and CRSII5_183478 to B.B.) and the Swiss MS Society Research grant (to F.I.). F.I. received a PhD fellowship from the Studienstiftung des deutschen Volkes. T.O. has grant support from the Swedish Research council and the Knut and Alice Wallenberg foundation and the Swedish Brain Foundation and Margaretha af Ugglas Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All donors had given written informed consent and the study was approved by the regional ethical review board of Stockholm (MS dnr. 2009/2107-21/2, last amendment dnr. 2022-03650-02; MG 2016-827-31) and Basel (Ref.Nr. EK: 49/06), respectively.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Mass cytometry data of the discovery and validation cohort will be made publicly available upon publication. Custom analysis code to reproduce the analysis will be uploaded to a public repository.
